RAPHOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Raphael Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.51+0.11 (+7.86%)
Close on Oct 16, 2026
- Market cap
- $30.47M
- P/E (TTM)
- 75.5
- Dividend yield
- –
Share price
+$1.11 (+277.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $30.47M
- P/E ratio
- 75.5
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$980.00K
- EPS, diluted
- $0.02
- Book value per share
- -$0.09
- Diluted shares
- 20M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$927.00K
Net income
-$980.00K
EPS, diluted
$0.02-33.3% YoY
Free cash flow
–
Reported periodTrailing twelve months